Home > Press > H&H Group Invests Additional $2,500,000 in Molecular Imprints
Total investment in Molecular Imprints $4.5 million
Harris & Harris Group Invests Additional $2,500,000 in Molecular Imprints
September 21, 2005
Harris & Harris Group, Inc.®, announced today that it invested an
additional $2,500,000 in privately held Molecular Imprints, Inc., of
Austin, TX, bringing its total investment in Molecular Imprints to
$4,500,000. The investment was as part of a Series C financing that
raised $17 million in the first closing of a planned $25 million
Series C financing. Molecular Imprints provides enabling
lithography systems for manufacturing applications in: nano devices,
LEDs for solid state lighting, magnetic data storage for micro disk
drives and others. Other investors participating in this financing
include Dai Nippon Printing Company (DNP), Alloy Ventures, Motorola
Ventures, Draper Fisher Jurvetson, Hakuto Co., Ltd., Asset
Management and others. Molecular Imprints will use the money to
expand its Imprio® product line.
Harris & Harris Group is a publicly traded venture capital company
that now makes initial investments exclusively in tiny technology,
including nanotechnology, microsystems and microelectromechanical
systems (MEMS). The Company's last 24 initial private equity
investments have been in tiny-technology enabled companies. The
Company has 20,756,345 shares of common stock outstanding.
Detailed information about Harris & Harris Group and its holdings
can be found on its website at www.TinyTechVC.com.
This press release may contain statements of a forward-looking
nature relating to future events. These forward-looking statements
are subject to the inherent uncertainties in predicting future
results and conditions. These statements reflect the Company's
current beliefs, and a number of important factors could cause
actual results to differ materially from those expressed in this
press release. Please see the Company's Annual Report on Form 10-K
for the fiscal year ended December 31, 2004, filed with the
Securities and Exchange Commission, for a more detailed discussion
of the risks and uncertainties associated with the Company's
business, including but not limited to the risks and uncertainties
associated with venture capital investing and other significant
factors that could affect the Company's actual results. Except as
otherwise required by Federal securities laws, Harris & Harris
Group, Inc.®, undertakes no obligation to update or revise these
forward-looking statements to reflect new events or uncertainties.
The reference to the website www.TinyTechVC.com has been provided as
a convenience, and the information contained on such website is not
incorporated by reference into this press release.
Copyright © Harris & Harris Group
If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
180 Degree Capital Corp. Announces the Start of Kevin Rendino as Chairman and Chief Executive Officer and Completion of its Transition to a Registered Closed-End Fund March 31st, 2017
Harris & Harris Group Issues Its Financial Statements as of December 31, 2016, Posts Its Annual Shareholder Letter, And Will Host a Conference Call for Shareholders on Friday, March 17, 2017 March 15th, 2017
Harris & Harris Group Announces the Filing of Preliminary Proxy Materials Detailing Its Proposed Conversion From a BDC to a Registered Closed-End Fund January 24th, 2017
Harris & Harris Group Issues Reminder for Shareholder Update Call on January 10, 2017 January 10th, 2017
Geoffrey Beach: Drawn to explore magnetism: Materials researcher is working on the magnetic memory of the future April 25th, 2017
Using light to propel water : With new method, MIT engineers can control and separate fluids on a surface using only visible light April 25th, 2017
Graphene holds up under high pressure: Used in filtration membranes, ultrathin material could help make desalination more productive April 24th, 2017
Nanoparticle vaccine shows potential as immunotherapy to fight multiple cancer types April 24th, 2017